After a $134M IPO, Seres settles into a new R&D shop

Seres Therapeutics ($MCRB), one of the year's IPO success stories, has leased an 83,000-square-foot R&D outpost in its native Cambridge, MA, pressing forward with a pipeline of microbiome treatments. As the Boston Business Journal reports, Seres has signed up to become the final tenant in a BioMed Realty-owned building that is also home to AbbVie ($ABBV), CRISPR Therapeutics, Synlogic and RaNA Therapeutics. Seres is in Phase II with SER-109, a Tylenol-sized capsule designed to treat recurrent Clostridium difficile infections by changing patients' bacterial makeup. Story

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.